Your browser doesn't support javascript.
loading
Regional citrate-calcium anticoagulation during polymyxin-B hemoperfusion: A case series.
Forfori, Francesco; Brogi, Etrusca; Sidoti, Anna; Giraudini, Martina; Monti, Gianpaola; Zarrillo, Nadia; Cantaluppi, Vincenzo; Ronco, Claudio.
Afiliación
  • Forfori F; 1 Department of Anesthesia and Intensive Care, University of Pisa, Pisa, Italy.
  • Brogi E; 1 Department of Anesthesia and Intensive Care, University of Pisa, Pisa, Italy.
  • Sidoti A; 1 Department of Anesthesia and Intensive Care, University of Pisa, Pisa, Italy.
  • Giraudini M; 1 Department of Anesthesia and Intensive Care, University of Pisa, Pisa, Italy.
  • Monti G; 2 Department of Anesthesiology and Intensive Care, Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy.
  • Zarrillo N; 3 Department of Anesthesia and Intensive Care, Hospital Sant'Anna and San Sebastiano Caserta, Caserta, Italy.
  • Cantaluppi V; 4 Division of Nephrology and Transplantation, Department of Translational Medicine, University of Eastern Piedmont (UPO), Novara, Italy.
  • Ronco C; 5 Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.
Int J Artif Organs ; 41(6): 319-324, 2018 Jun.
Article en En | MEDLINE | ID: mdl-29577795
INTRODUCTION: So far, only heparin-based anticoagulation has been proposed during polymyxin-B hemoperfusion. However, postsurgical septic patients can be at high risk of bleeding due to either surgical complications or septic coagulation derangement. Consequently, heparin should not represent in some cases the anticoagulation regimen of choice in this type of patients. METHODS AND RESULTS: We present a case series of four postsurgical septic patients treated with polymyxin-B hemoperfusion using regional citrate anticoagulation. All the treatments were performed without complications. During each treatment, there were no episodes of filter clotting, no bleeding, and no metabolic complications for any of the patients. CONCLUSION: To our knowledge, this is the second published report on the use of citrate anticoagulation during polymyxin-B hemoperfusion. Our case series continued to show that regional citrate anticoagulation regimen is feasible and safe during polymyxin-B hemoperfusion treatment in postsurgical septic patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polimixina B / Choque Séptico / Coagulación Sanguínea / Hemoperfusión / Ácido Cítrico / Anticoagulantes Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Artif Organs Año: 2018 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polimixina B / Choque Séptico / Coagulación Sanguínea / Hemoperfusión / Ácido Cítrico / Anticoagulantes Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Artif Organs Año: 2018 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos